{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:32:31Z","timestamp":1789428751826,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40265-021-01552-8","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T06:04:02Z","timestamp":1626847442000},"page":"1343-1348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Pamiparib: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/1179554921996288","author":"Z Wu","year":"2021","unstructured":"Wu Z, Cui P, Tao H, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021. https:\/\/doi.org\/10.1177\/1179554921996288.","journal-title":"Clin Med Insights Oncol"},{"key":"1552_CR2","unstructured":"Businesswire. China NMPA approves PARP inhibitor pamiparib for patients with previously treated advanced ovarian cancer [media release]. May 7 2021. https:\/\/www.businesswire.com."},{"key":"1552_CR3","unstructured":"BeiGene. Pamiparib: prescribing information. 2021."},{"issue":"9","key":"1552_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","volume":"22","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Guo Y, Liu Y, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020;22(9):431\u201340.","journal-title":"Neoplasia"},{"issue":"24","key":"1552_CR5","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1021\/acs.jmedchem.0c01346","volume":"63","author":"H Wang","year":"2020","unstructured":"Wang H, Ren B, Liu Y, et al. Discovery of pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development. J Med Chem. 2020;63(24):15541\u201363.","journal-title":"J Med Chem"},{"key":"1552_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.943","author":"S Mu","year":"2021","unstructured":"Mu S, Palmer D, Fitzgerald R, et al. Human mass balance and metabolite profiling of [14C]-pamiparib, a poly (ADP-ribose) polymerase inhibitor, in patients with advanced cancer. Clin Pharmacol Drug Dev. 2021. https:\/\/doi.org\/10.1002\/cpdd.943.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1552_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04253-x","author":"S Mu","year":"2021","unstructured":"Mu S, Lin C, Skrzypczyk-Ostaszewicz A, et al. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study. Cancer Chemother Pharmacol. 2021. https:\/\/doi.org\/10.1007\/s00280-021-04253-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1552_CR8","doi-asserted-by":"crossref","unstructured":"Wu X, Zhu J, Wang J, et al. Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC) [abstract no. 820P and Poster]. Ann Oncol. 2020;31 (Suppl 4):S619\u201320.","DOI":"10.1016\/j.annonc.2020.08.959"},{"issue":"1","key":"1552_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cam4.3575","volume":"10","author":"B Xu","year":"2021","unstructured":"Xu B, Yin Y, Dong M, et al. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. Cancer Med. 2021;10(1):109\u201318.","journal-title":"Cancer Med"},{"key":"1552_CR10","doi-asserted-by":"crossref","unstructured":"Voskoboynik M, Mileshkin L, Gan H, et al. Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1\/2 inhibitor, in patients (pts) with advanced solid tumours: updated phase I dose-escalation\/expansion results [abstract no. 452PD]. Ann Oncol. 2019;30(Suppl 5):v167.","DOI":"10.1093\/annonc\/mdz244.014"},{"key":"1552_CR11","unstructured":"BeiGene. BeiGene announces preliminary clinical data on PARP inhibitor pamiparib presented at annual scientific meeting and education day of the Society for Neuro-Oncology [media release]. 16 Nov 2018. http:\/\/www.beigene.com."},{"issue":"9","key":"1552_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","volume":"20","author":"M Friedlander","year":"2019","unstructured":"Friedlander M, Meniawy T, Markman B, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial. Lancet Oncol. 2019;20(9):1306\u201315.","journal-title":"Lancet Oncol"},{"key":"1552_CR13","doi-asserted-by":"crossref","unstructured":"Stradella A, Johnson M, Goel S, et al. Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1\/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ) [abstract no. 530MO]. Ann Oncol. 2020;31(Suppl 4):S465\u20136.","DOI":"10.1016\/j.annonc.2020.08.644"},{"key":"1552_CR14","unstructured":"Myriad Genetics. Myriad Genetics and BeiGene sign agreement to develop companion diagnostics for use with BeiGene\u2019s novel PARP Inhibitor, BGB-290 [media release]. 06 Apr 2017. https:\/\/myriad.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01552-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01552-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01552-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T09:29:24Z","timestamp":1627464564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01552-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01552-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"21 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}